Summary
Explores applications of Artificial Intelligence/Machine Learning across drug and biological product development (e.g., trial design, data integrity, pharmacovigilance), poses questions for stakeholder feedback, and outlines future policy considerations.
Healthcare Implications
Signals regulatory expectations for AI use in clinical trials and manufacturing; sponsors should plan for transparency, validation, and risk management for AI‑enabled methods.